Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Post by GameChangerBeton May 15, 2021 9:19am
389 Views
Post# 33209599

Understand Your Bet

Understand Your BetThe bet here, is that Phase lll will be successful. That's it. If they are successful, everything becomes validated and the door bursts wide open, if they fail, the story, at least on the surface is over.
Until that point is reached, understand there are many necessary processes, including equity raises.
Here's an analogy:
You've made a bet on a Football game for a specific team to win the game. That's your bet.
There are four quarters of play. In the game, your team might be winning, they might be losing, it may go back and forth, they might fumble the ball, they might miss a field goal. Understand these are normal and expected events. The end result, the final score is what matters. If your team wins the game, they move on to the playoffs, the Superbowl. Understand?

If Antibe is successful with Phase lll, the market will have no choice but to assign it's proper value accordingly.

Personally, that is where my focus is and will remain. The final score. I am not concerned in the least about the interim.

Bottom line, you need to do a self assessment and have a clear, and thorough understanding of what it is that you have bet on. 
Is it the final score? Or is it live betting where you're making play by play bets.
<< Previous
Bullboard Posts
Next >>